For example, Patisiran, a siRNA-based gene therapy, treats amyloidotic polyneuropathy, by silencing Transthyretin (TTR) gene5, and Givosiran is also a siRNA-based gene drug to cure acute hepatic porphyria by targeting δ-aminolevulinate synthase 1 (ALAS1).6 This evidence concerns the gene TTR and Acute hepatic porphyria.